Browsing by Subject "sirolimus"
Now showing items 1-10 of 18
-
Análise prospectiva do perfil de segurança do estudo de conversão planejada do regime imunossupressor com base no sirolimo introduzido 3 meses após transplante renal, em comparação com um regime contínuo com base no tacrolimo em pacientes com novo transpl
(Universidade Federal de São Paulo (UNIFESP), 2016-06-30)The safety and tolerability of immunosuppressive regimens derive from complex interactions of factors including known drug-related off-target adverse events, drug doses/concentrations and combinations, demography and time ...
-
Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation
(Wiley-Blackwell, 2009-08-01)The Symphony study showed that at 1 year posttransplant, a regimen based on daclizumab induction, 2 g mycophenolate mofetil (MMF), low-dose tacrolimus and steroids resulted in better renal function and lower acute rejection ...
-
Concentration-controlled use of sirolimus associated with reduced exposure of cyclosporine in black recipients of primarily living renal allograft donors: 12-month results
(Blackwell Publishing, 2005-10-01)Aim: This study was designed to identify optimal therapeutic sirolimus (SRL) concentrations in black kidney transplant recipients on reduced cyclosporine (CsA) exposure and prednisone.Methods: Seventy patients (64 living/six ...
-
Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients
(Wiley-Blackwell, 2009-10-01)This study was conducted to evaluate the pharmacokinetics (pk) and drug interactions between cyclosporine (CsA) and sirolimus (SRL) in kidney transplant recipients. the morning (a.m.) and evening (p.m.) pk of CsA (4-5 ...
-
Decreased Cytomegalovirus infection after antilymphocyte therapy in sirolimus-treated renal transplant patients
(Elsevier B.V., 2005-01-01)Cytomegalovirus (CMV) infection is highly prevalent in transplant patients, especially in those submitted to a more intense immunosuppression. We monitored CMV infection in 34 patients during 60 days after antilymphocyte ...
-
Eficácia, tolerabilidade e segurança do uso do sirolimo após o transplante renal
(Sociedade Brasileira de Nefrologia, 2009-12-01)INTRODUCTION: Sirolimus (SRL) is an immunosuppressive drug with confirmed efficacy and safety profile in the prophylaxis of acute rejection after renal transplantation. OBJECTIVES: To assess the efficacy, safety, and ...
-
Fundamento e desenho do teste randomizado PAINT
(Sociedade Brasileira de Cardiologia - SBC, 2009-12-01)BACKGROUND: We describe the rationale and design for the PercutAneous INTervention with biodegradable-polymer based paclitaxel-eluting or sirolimus-eluting versus bare stents for de novo coronary lesions - PAINT trial. ...
-
Impacto dos stents e do sirolimus por via oral na vasomotilidade coronariana dependente e independente do endotelio
(Sociedade Brasileira de Cardiologia - SBC, 2012-04-01)BACKGROUND: There is no consensus regarding the impact of stenting on long-term endothelial function. There have been reports of increased endothelial dysfunction with sirolimus-eluting stents as compared to bare metal ...
-
Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation
(Lippincott Williams & Wilkins, 2016)Background:Long-term efficacy and safety of de novo use of the mammalian target of rapamycin inhibitors (mTORi) have been evaluated primarily using registry data.Methods:This was a pooled retrospective analysis of data ...
-
Long-Term Follow-Up of De Novo Use of mTOR and Calcineurin Inhibitors After Kidney Transplantation
(Lippincott Williams & Wilkins, 2016)Background:Long-term efficacy and safety of de novo use of the mammalian target of rapamycin inhibitors (mTORi) have been evaluated primarily using registry data.Methods:This was a pooled retrospective analysis of data ...